Johnson & Johnson’s pullback from RSV research thins the pack of companies aiming to develop a vaccine for the pathogen. GSK and Pfizer have vaccines under FDA review and a shot from Moderna could soon follow.
J&J Portfolio Review Culls RSV Vaccine, Ending the Phase 3 Program
